nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.07.2008 | Original Article

Role of [¹⁸F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results

verfasst von: Laura L. Travaini, Giuseppe Trifirò, Laura Ravasi, Lorenzo Monfardini, Paolo Della Vigna, Guido Bonomo, Antonio Chiappa, Andrew Mallia, Mahila Ferrari, Franco Orsi, Giovanni Paganelli

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Focal metastasis may be treated with radiofrequency ablation (RFA), a low invasive method yet limited by the lack of direct evidence of radicality of treatment. We, hereby, aimed at assessing the role of positron emission tomography–computed tomography (PET/CT) with fluoride radiolabeled deoxy-glucose ([¹⁸F]FDG) in RFA treatment success evaluation and early diagnosis of local relapse of liver metastasis after RFA procedure.

Methods

RFA was performed in nine patients on 12 liver metastasis, serially imaged through [¹⁸F]FDG-PET/CT and multidetector CT (MDCT) at 1, 3, 6, and 9 months after treatment. Eight lesions were also scanned with [¹⁸F]FDG-PET/CT at 1 week after treatment. Imaging analyses were performed on 47 [¹⁸F]FDG-PET/CT and 51 MDCT. Imaging reading outcomes were compared to each other and to biopsy tissue results when available.

Results

In one case, [¹⁸F]FDG-PET/CT revealed radiotracer uptake at RFA site a week after procedure. Negative concordant outcome was obtained on eight lesions at 1 month after RFA, on eight cases at 3 months, on four at 6 months, and on two cases at 9 months. Extra-liver (peritoneal) disease was detected in one case by both [¹⁸F]FDG-PET/CT and MDCT. In seven cases, [¹⁸F]FDG-PET/CT revealed the presence of local recurrence earlier than MDCT. In no cases did MDCT detect local relapse earlier than [¹⁸F]FDG-PET/CT.

Conclusion

[¹⁸F]FDG-PET/CT may detect RFA treatment failure as well as local relapse after RFA earlier than MDCT.

Wilson SM, Adson Ma. Surgical treatment of hepatic metastases from colorectal cancer. Arch Surg. 1976;111:330–4.PubMed

Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.PubMedCrossRef

Primrose JN. Treatment of colorectal metastases: surgery, cryotherapy, or radiofrequency ablation. Gut. 2002;50:1–5.PubMedCrossRef

Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg. 2000;231:743–51.PubMedCrossRef

Ravikumar TS, Steele G, Kane R, King V. Experimental and clinical observations on hepatic surgery for colorectal cancer. Cancer Res. 1991;51:6323–7.PubMed

Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases. Hepatogastroenterology. 2001;48:333–7.PubMed

Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: Indications, limitations, and complications. Ann Surg Oncol 2000;7:593–600.PubMed

Solbiati L, Ierace T, Tonolini M, Osti V, Cova L. Radiofrequency thermal ablation of hepatic metastases. Eur J Ultrasound. 2001;13:149–58.PubMedCrossRef

Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg. 2001;233:293–9.PubMedCrossRef

10.

Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, et al. Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol. 2002;20:388–95.PubMedCrossRef

11.

Wiering B, Ruers TJ, Oven WJ. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases. Expert Rev Anticancer Ther. 2004;4:607–13.PubMedCrossRef

12.

Kantorova I, Lipska L, Belohlavek O, Visokai V, Trubac M, Schneiderova M. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med. 2003;44:1784–8.PubMed

13.

Arulampalam TH, Francis DL, Visvikis D, Taylor I, Ell PJ. FDG-PET for the pre-operative evaluation of colorectal liver metastases. Eur J Surg Oncol. 2004;30:286–91.PubMedCrossRef

14.

Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carried-added 2-[18F]-fluoro-2-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235–8.PubMed

15.

Kamel E, Hany TF, Burger C, Treyer V, Lonn AH, von Schulthess GK, et al. CT vs 68Ge attenuation correction in a combined PET/CT system: evaluation of the effect of lowering the CT tube current. Eur J Nucl Med Mol Imaging. 2002;29:346–50.PubMedCrossRef

16.

Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43:1348–60.PubMedCrossRef

17.

Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, et al. Importance of CEA and CA 15–3 during disease progression in metastatic breast cancer patients. Anticancer Res. 2007;27:1963–8.PubMed

18.

Antoch G, Vogt FM, Veit P, Freudenberg LS, Blechschmid N, Dirsch O, et al. Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. Nucl Med. 2005;46:520–5.

19.

Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol. 2006;16:80–7.PubMedCrossRef

20.

Anderson GS, Brinkman F, Soulen MC, Alavi A, Zhuang H. FDG Positron Emission Tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nuc Med. 2003;28:192–7.CrossRef

21.

Donckier V, Van Laethem JL, Goldman S, Van Gansbeke D, Feron P, Ickx B, et al. [F-18] Fluorodeoxyglucose Positron Emission Tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. Journal Surg Onc. 2003;84:215–23.CrossRef

22.

Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004;240:1027–35.PubMedCrossRef

23.

Takahashi S, Kuroki Y, Nasu K, Nawano S, Konishi M, Nakagohri T, et al. Positron emission tomography with F-18 fluorodeoxyglucose in evaluating colorectal hepatic metastasis down-staged by chemotherapy. Anticancer Res. 2006;26:4705–11.PubMed

24.

Zanotti-Fregonara P, Hindié E, Albertini AF, Ech-Charraq I, Weinmann P, Devaux JY. FDG (18)F-FDG PET/CT visualisation of tumor seeding after percutaneous radiofrequency ablation of metastases. Eur J Nucl Med Mol Imaging. 2007;34:305.PubMedCrossRef

Titel: Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results
verfasst von: Laura L. Travaini
Giuseppe Trifirò
Laura Ravasi
Lorenzo Monfardini
Paolo Della Vigna
Guido Bonomo
Antonio Chiappa
Andrew Mallia
Mahila Ferrari
Franco Orsi
Giovanni Paganelli
Publikationsdatum: 01.07.2008
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2008
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-008-0748-7

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2008

18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: Is dual time point imaging worth the effort?

Is absolute quantification of dopaminergic neurotransmission studies with 123I SPECT ready for clinical use?

188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases

ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine

The power of synergy in the mediastinal staging of lung cancer

The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism